Page 509 - Read Online

Page 6 of 6 Lin et al. Hepatoma Res 2018;4:48 I http://dx.doi.org/10.20517/2394-5079.2018.19

and without HIV infection. Am J Gastroenterol 2010;105:1346-53.
10. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation
of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver
disease. World J Gastroenterol 2005;11:476-81.
11. Huang H, Wu T, Mao J, Fang Y, Zhang J, Wu L, Zheng S, Lin B, Pan H. CHI3L1 is a liver-enriched, noninvasive biomarker that can be
used to stage and diagnose substantial hepatic fibrosis. OMICS 2015;19:339-45.
12. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, Group H-CT. Serum
fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-9.
13. Wang L, Liu T, Zhou J, You H, Jia J. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two
established quantitative methods in chronic hepatitis B patients following antiviral therapy. Hepatol Res 2018;48:E283-29.
14. Pungpapong S, Nunes DP, Krishna M, Nakhleh R, Chambers K, Ghabril M, Dickson RC, Hughes CB, Steers J, Nguyen JH, Keaveny AP.
Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008;14:1294-302.
15. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with
hepatic fibrosis. J Hepatol 2000;32:911-20.
16. He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y, Nour AM, Parikh CR, Schmidt I,
Modis Y, Cantley L, Elias JA. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep 2013;4:830-41.